NCT00620581View on ClinicalTrials.gov

Luteal Phase Administration of Paroxetine for the Treatment of PMDD

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Premenstrual Dysphoric Disorder
Interventions
DRUG

Paroxetine

Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle

Trial Locations (1)

L8N 4A6

Women's Health Concerns Clinic, Hamilton

All Listed Sponsors
lead

Hamilton Health Sciences Corporation

OTHER